This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2007 Oct;5(10):772-4.

mTOR as a target for therapy of renal cancer

Affiliations

PMID: 17998894

mTOR as a target for therapy of renal cancer

Gary R Hudes. Clin Adv Hematol Oncol. 2007 Oct.

. 2007 Oct;5(10):772-4.

Author

Affiliation

¹ Genitourinary Malignancies Program, Fox Chase Cancer Center, Philadelphia, PA, USA.

PMID: 17998894

No abstract available

PubMed Disclaimer

Similar articles

Targeting mTOR in renal cell carcinoma.
Hudes GR. Hudes GR. Cancer. 2009 May 15;115(10 Suppl):2313-20. doi: 10.1002/cncr.24239. Cancer. 2009. PMID: 19402072 Review.
Combination targeted therapy in advanced renal cell carcinoma.
Sosman J, Puzanov I. Sosman J, et al. Cancer. 2009 May 15;115(10 Suppl):2368-75. doi: 10.1002/cncr.24234. Cancer. 2009. PMID: 19402058 Review.
Targeted inhibition of mammalian target of rapamycin for the treatment of advanced renal cell carcinoma.
Kapoor A, Figlin RA. Kapoor A, et al. Cancer. 2009 Aug 15;115(16):3618-30. doi: 10.1002/cncr.24409. Cancer. 2009. PMID: 19479976 Review.
Signal transduction pathways: signposts to improved therapy for advanced renal cell carcinoma.
Oestreicher P. Oestreicher P. ONS Connect. 2007;22(8 Suppl):35-6. ONS Connect. 2007. PMID: 17824556 Review. No abstract available.
New mTOR inhibitor for renal cell cancer.
Wilkes GM. Wilkes GM. Oncology (Williston Park). 2009 Jul;23(8 Suppl):54-6. Oncology (Williston Park). 2009. PMID: 19860046 No abstract available.

See all similar articles

Cited by

Dysregulation of mRNA translation and energy metabolism in cancer.
Leibovitch M, Topisirovic I. Leibovitch M, et al. Adv Biol Regul. 2018 Jan;67:30-39. doi: 10.1016/j.jbior.2017.11.001. Epub 2017 Nov 2. Adv Biol Regul. 2018. PMID: 29150352 Free PMC article. Review.
eIF4E knockdown decreases breast cancer cell growth without activating Akt signaling.
Soni A, Akcakanat A, Singh G, Luyimbazi D, Zheng Y, Kim D, Gonzalez-Angulo A, Meric-Bernstam F. Soni A, et al. Mol Cancer Ther. 2008 Jul;7(7):1782-8. doi: 10.1158/1535-7163.MCT-07-2357. Mol Cancer Ther. 2008. PMID: 18644990 Free PMC article.
Suppression of T-cell responses by tumor metabolites.
Singer K, Gottfried E, Kreutz M, Mackensen A. Singer K, et al. Cancer Immunol Immunother. 2011 Mar;60(3):425-31. doi: 10.1007/s00262-010-0967-1. Epub 2011 Jan 15. Cancer Immunol Immunother. 2011. PMID: 21240484 Free PMC article. Review.
IMPA2 Downregulation Enhances mTORC1 Activity and Restrains Autophagy Initiation in Metastatic Clear Cell Renal Cell Carcinoma.
Kuei CH, Lin HY, Lee HH, Lin CH, Zheng JQ, Chen KC, Lin YF. Kuei CH, et al. J Clin Med. 2020 Mar 30;9(4):956. doi: 10.3390/jcm9040956. J Clin Med. 2020. PMID: 32235551 Free PMC article.
Rationale-based therapeutic combinations with PI3K inhibitors in cancer treatment.
Castel P, Toska E, Zumsteg ZS, Carmona FJ, Elkabets M, Bosch A, Scaltriti M. Castel P, et al. Mol Cell Oncol. 2014 Oct 29;1(3):e963447. doi: 10.4161/23723548.2014.963447. eCollection 2014 Jul-Sep. Mol Cell Oncol. 2014. PMID: 27308344 Free PMC article. Review.

See all "Cited by" articles

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Other Literature Sources
- The Lens - Patent Citations Database
Medical
- MedlinePlus Health Information
Miscellaneous
- NCI CPTAC Assay Portal